Abstract: A beverage dispenser adapter having at least one pump having a connector for electrical connection to an induction coil in the dispenser base dispensing a predefined amount of formula for mixing with a liquid, a formula carton connector for connecting a carton containing formula for beverage preparation, an elongated dispensing tube in a housing for fitting within the induction coil, and a controller for controlling amounts and ratios of formula and liquid upon selection of a beverage by a user.

Abstract: A beverage dispenser adapter having at least one pump having a connector for electrical connection to an induction coil in the dispenser base dispensing a predefined amount of formula for mixing with a liquid, a formula carton connector for connecting a carton containing formula for beverage preparation, an elongated dispensing tube in a housing for fitting within the induction coil, and a controller for controlling amounts and ratios of formula and liquid upon selection of a beverage by a user.

Abstract: A running tool includes a tool body having a fluid conduit, and an actuation assembly including an actuator member connected to a release mechanism, the actuator member moveable in an axial direction from a first position to a second position to cause the release mechanism to disengage with a downhole component. The actuation assembly includes a first pressure chamber in pressure communication with the fluid conduit, where the running tool is configured to be activated to release the downhole component by applying fluid pressure to the first pressure chamber to generate an actuation force that moves the actuator member to the second position. The running tool also includes a second pressure chamber in pressure communication with the same fluid conduit. The second pressure chamber is configured to receive borehole fluid from the fluid conduit during deployment and apply a balancing force to the actuator member during the deployment.

Abstract: Provided are engineered novel forms of the acidic mammalian chitinase having enhanced expression and having improved catalytic activity. The novel forms of the mammalian acidic chitinase comprise one or more amino acid substitutions, relative to the native sequence, that impart these improved properties. The novel proteins may be used therapeutically for the prevention and treatment of airway conditions associated with environmental chitin exposure and accumulation.

Abstract: A running tool includes a tool body having a fluid conduit, and an actuation assembly including an actuator member connected to a release mechanism, the actuator member moveable in an axial direction from a first position to a second position to cause the release mechanism to disengage with a downhole component. The actuation assembly includes a first pressure chamber in pressure communication with the fluid conduit, where the running tool is configured to be activated to release the downhole component by applying fluid pressure to the first pressure chamber to generate an actuation force that moves the actuator member to the second position. The running tool also includes a second pressure chamber in pressure communication with the same fluid conduit. The second pressure chamber is configured to receive borehole fluid from the fluid conduit during deployment and apply a balancing force to the actuator member during the deployment.

Abstract: Embodiments of the present disclosure generally relate to apparatus and methods for manufacturing continuous sucker rods with protective coatings. One embodiment provides a coating system including a first drive station disposed on a first end of a coating line, a second drive station disposed on a second end of the coating line to move a continuous sucker rod along the coating line from the first drive station to the second drive station, a heater disposed along the coating line, and a first coating station disposed along the coating line.

Abstract: A method and assembly for frequency stabilization of an optical signal especially from a laser, the assembly (11) comprising beam splitter (15), a passive frequency discriminator (16), and a pair of photodiodes (17 & 18). The beam splitter (15) in use receives a collimated optical beam (B) and diverts a sample beam (B1) which is directed towards the discriminator (16) which transmits a portion (B2) of said sample beam to one of the photodiodes (17) and reflects a second portion (B3) of said sample beam to the other photodiode (18). A control signal (S3) is derived from the respective intensities of the transmitted and reflected portions of the sample beam, and utilized to operate the electronic control to adjust the frequency of the laser output signal, if required, to maintain a specified frequency.

Abstract: A wavelength locker for locking the wavelength of a light beam substantially to a predetermined wavelength comprises at east one Fabry-Perot etalon arranged to receive a sample portion of the light beam and to produce at least one output light beam therefrom, the intensity of which is dependent upon the wavelength of the sample light beam, the Fabry-Perot etalon comprising diamond. Preferably the diamond etalon is a single crystal synthetic diamond having highly polished input and output faces without any reflective coatings.

Abstract: A method and assembly for frequency stabilisation of an optical signal especially from a laser, the assembly (11) comprising beam splitter (15), a passive frequency discriminator (16), and a pair of photodiodes (17 & 18). The beam splitter (15) in use receives a collimated optical beam (B) and diverts a sample beam (B1) which is directed towards the discriminator (16) which transmits a portion (B2) of said sample beam to one of the photodiodes (17) and reflects a second portion (B3) of said sample beam to the other photodiode (18). A control signal (S3) is derived from the respective intensities of the transmitted and reflected portions of the sample beam, and utilised to operate the electronic control to adjust the frequency of the laser output signal, if required, to maintain a specified frequency.

Abstract: A method for identifying compounds capable of inducing immunosuppression by inhibiting the CD28 signal transduction pathway and T cell comprises exposing cultured T cells to one or more test compounds. The T cells are obtained from a T cell line which stably incorporates DNA sequence comprising in reading frame an enhancer region responsive to a CD28-regulated nuclear binding protein and a marker gene. The cells are cultured under conditions which result in activation of both the T cell receptor and the CD28 receptor, resulting in enhanced expression of the marker gene. Test compounds which inhibit expression of the marker gene are considered as candidates for immunosuppressive drugs.

Abstract: Quinolones with antihypertensive activity have the general formula I, ##STR1## wherein X is the residue of an optionally substituted benzene ring; R is lower alkyl; R.sub.3 is hydrogen or lower alkyl; R.sub.1 and R.sub.2, which may be the same or different, are hydrogen, lower alkyl, or, together with the nitrogen atom to which they are attached, form a 5 to 7 membered saturated heterocyclic ring optionally containing an additional hetero atom selected from nitrogen, oxygen and sulphur and optionally substituted by 1 or more lower alkyl groups; and the dotted line between positions 2 and 3 of the quinolone nucleus represents an optional bond. The compounds are useful as antihypertensive agents. They are also indicated for use in treating heart failure and ischaemic heart disease.

Abstract: Novel thienopyridones with antihypertensive activity have the formula I, ##STR1## wherein the ring A represents an optionally substituted thiophene ring; m is 0 or 1; n is 0, 1 or 2; R is lower alkyl and R.sub.1 is lower alkyl.The fused thieno-ring may carry one or two substituents.Formula I encompasses thieno[3,2-b]pyridones, thieno[3,4-b]pyridones and thieno[2,3-b]pyridones.Processes for preparing the novel thienopyridones and pharmaceutical compositions containing them are described. Pharmaceutically acceptable acid addition salts of the compounds of formula I are also described.The thienopyridones of formula I are antihypertensive agents and are also indicated for use in treating heart failure and ischaemic heart disease.

Abstract: Compositions which contain a quinolone compound of the general formula ##STR1## wherein n is 0, 1 or 2; R.sub.1 is lower alkyl optionally substituted by hydroxy or C.sub.1-4 alkoxycarbonyl; allyl; propynyl or phenyl- lower alkyl in which the phenyl ring is optionally substituted by 1 or 2 C.sub.1-4 alkoxy groups; R.sub.2 is C.sub.1-4 alkyl with the proviso that when n is 0, R.sub.2 is methyl; and R.sub.3, R.sub.4 and R.sub.5, which may be the same or different, are hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, halo, trifluoromethyl or lower alkylthio show antihypertensive activity.Compounds of general formula ##STR2## in which n, R.sub.1 R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as described above are novel subject to the following provisos (a) when R.sub.3, R.sub.4 and R.sub.4 and R.sub.5 are hydrogen R.sub.2 is methyl and R.sub.1 is lower alkyl, R.sub.1 contains more than one carbon atom, and(b) when R.sub.3 and R.sub.4 are hydrogen, R.sub.5 is hydrogen or 7-methyl, and R.sub.1 is ethyl, R.sub.